Last €39.77 EUR
Change Today +0.367 / 0.93%
Volume 0.0
I7G On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
Stuttgart
As of 7:49 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

ipsen (I7G) Snapshot

Open
€38.85
Previous Close
€39.40
Day High
€39.77
Day Low
€38.83
52 Week High
10/1/14 - €39.83
52 Week Low
10/2/13 - €28.32
Market Cap
3.3B
Average Volume 10 Days
43.6
EPS TTM
--
Shares Outstanding
82.8M
EX-Date
06/9/14
P/E TM
--
Dividend
€0.80
Dividend Yield
2.03%
Current Stock Chart for IPSEN (I7G)

Related News

No related news articles were found.

ipsen (I7G) Related Businessweek News

View More BusinessWeek News

ipsen (I7G) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,600 Employees
Last Reported Date: 08/29/14
Founded in 1929

ipsen (I7G) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen (I7G) Key Developments

Ipsen Presents Preliminary Results of Exploratory Proof-Of-Concept Study with Tasquinimod in Four Advanced Tumor Types at the ESMO 2014 Congress

Ipsen announced the presentation at the ESMO 2014 Congress (26-30 September in Madrid) of the preliminary results of the phase II proof-of-concept clinical trial with tasquinimod in monotherapy, evaluating the compound in four advanced tumor types. The main objective of the study was to determine the clinical activity of tasquinimod in advanced hepatocellular (HCC), ovarian (OC), renal cell (RCC) and gastric (GC) carcinomas in patients who had progressed after standard anti-tumor therapies. Primary endpoint was the PFS rate at a predefined time for each cohort. Secondary objectives included PFS, response rate, OS, safety, pharmacokinetics and biomarkers. The data did not support further development of tasquinimod in monotherapy in heavily pretreated patients with advanced OC, RCC and GC. Pharmacokinetic and biomarkers analyses are ongoing. Preliminary results from the futility analysis reported sufficient clinical activity to complete the recruitment of the HCC cohort for which results are expected in 2015. The safety profile was consistent with the known safety profile of tasquinimod in previous studies. Data from the HCC cohort was presented (Poster p-171) at the International Liver Cancer Association 8(th) Annual Conference (5--7 September 2014, Kyoto, Japan).

Ipsen Bioscience Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Ipsen Bioscience Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Ipsen Announces Acceptance of Filings for Somatuline(R) in the Treatment of GEP-NET in the US with Priority Review and in Europe

Ipsen announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of its supplemental New Drug Application (sNDA) for Somatuline(R) Depot(R) 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA designates priority review status to drug candidates that have the potential to offer a significant improvement in treatment compared to currently approved options. Decision is expected in early first quarter of 2015. In the European Union, the dossier of the national marketing authorization (MA) variations for Somatuline(R) Autogel(R) 120mg injection has been validated by all national 25 drug regulatory authorities. The first decisions are expected by second quarter of 2015. The regulatory submissions and variations were supported by the results of the CLARINET(R) Phase III study, which demonstrated the antitumor effect of Somatuline(R) in the treatment of patients with GEP-NETs, and which was recently published in the July 17th issue of The New England Journal of Medicine. The data from CLARINET(R) is purely investigational, as Somatuline(R) is not authorized for the indication of treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in any market. In many countries where it is marketed as Somatuline(R) Autogel(R), Somatuline(R) is approved for treatment of acromegaly and for the symptoms associated with neuroendocrine tumors, which can include the treatment of GEP-NET patients experiencing symptoms from carcinoid syndrome, and Somatuline(R) is approved in many countries for the treatment of acromegaly. Somatuline(R) Depot is approved in the US for the treatment of acromegaly but not for the treatment of GEP-NETs or the symptoms thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I7G:GR €39.77 EUR +0.367

I7G Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.22 EUR -0.26
Meda AB kr100.00 SEK -1.80
Orion OYJ €30.88 EUR +0.19
Procter & Gamble Hygiene & Health Care Ltd 5,350 INR 0.00
Recordati SpA €12.78 EUR -0.15
View Industry Companies
 

Industry Analysis

I7G

Industry Average

Valuation I7G Industry Range
Price/Earnings 19.0x
Price/Sales 2.3x
Price/Book 3.0x
Price/Cash Flow 18.1x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.